Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: leaptx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2025 | Buy → Neutral | H.C. Wainwright | |
| 1/29/2025 | $9.00 → $1.25 | Outperform → Neutral | Robert W. Baird |
| 6/28/2024 | $8.00 | Buy | Rodman & Renshaw |
| 10/4/2021 | $6.00 | Buy | Mizuho |
| 9/14/2021 | $3.00 → $4.00 | Outperform | Raymond James |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
DEFA14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
424B5 - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
10-Q - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
DEFA14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
DEF 14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
PRE 14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright downgraded Leap Therapeutics from Buy to Neutral
Robert W. Baird downgraded Leap Therapeutics from Outperform to Neutral and set a new price target of $1.25 from $9.00 previously
Rodman & Renshaw initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $8.00
Mizuho initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $6.00
Raymond James reiterated coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $4.00 from $3.00 previously
Robert W. Baird resumed coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $5.00
Raymond James initiated coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $3.50
Raymond James reiterated coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $3.50 from $2.50 previously
Raymond James reiterated coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $3.50 from $2.50 previously
Fastest customizable press release news feed in the world
CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (NASDAQ:LPTX), a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash, today reported financial results for the third quarter of 2025 and a corporate update. As announced earlier today, the Company has changed its name to "Cypherpunk Technologies Inc." from "Leap Therapeutics, Inc." to reflect the strategic focus on acquiring the digital asset, ZEC, participating in the development of Zcash, and the values of privacy and liberty. The Company will begin trading on the Nasdaq Capital Market under the
Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cypherpunk Technologies Inc. announces acquisition of 203,775.27 ZEC. CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today announced it will change its name to Cypherpunk Technologies Inc., and unveiled a digital asset treasury strategy to accumulate Zcash's native coin, ZEC. Cypherpunk has to date used $50 million of proceeds from the previously announced private placement to purchase 203,775.27 ZEC at an average purchase price of $245.37 per ZEC. In addition, the company also plans to change its ticker symbol to (NASDAQ:CYPH) as part of t
Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Leap to continue supporting development of sirexatamab in DKK1-high CRC patients CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced final results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and ch
CAMBRIDGE, Mass., Oct. 9, 2025 /PRNewswire/ -- Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has closed its previously announced private placement led by Winklevoss Capital raising $58,888,888 in cash to initiate a digital asset treasury strategy. At the closing of the transaction, Leap issued (i) 15,212,311 shares of common stock (the "Shares"), (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 80,768,504 shares of common stock, and (ii) warrants to purchase an additional 71,985,605 shares of common stock at an exercise price of $0.5335 per share (the "War
CAMBRIDGE, Mass., Oct. 6, 2025 /PRNewswire/ -- Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced $58,888,888 in cash commitments for a private investment in public equity ("PIPE") offering led by Winklevoss Capital to initiate a digital asset treasury strategy. Leap has entered into a securities purchase agreement for the purchase and sale of (i) 95,849,353 shares of common stock (the "Purchased Shares") or pre-funded warrants in lieu thereof (the "Purchased Pre-Funded Warrants") and (ii) warrants to purchase an additional 71,887,008 shares of common stock at an exercise price of $0.5335 per share (the "P
CAMBRIDGE, Mass., Sept. 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present the final clinical results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) who have received one prior systemic therapy for advanced disease. The final results will be presented in a Mini Oral Session at the Europe
CAMBRIDGE, Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025. Leap Highlights: Board of Directors initiated process of exploring strategic alternatives to maximize shareholder valueStrategic restructuring to prioritize corporate development resulting in a further 75% reduction in workforceReported updated data from the randomized, controlled Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line colorectal cancer (CRC)"This past quarter, we undertook a strategic
Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated process to explore strategic alternatives to maximize shareholder value CAMBRIDGE, Mass., June 23, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported updated results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and ch
CAMBRIDGE, Mass., May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025. Leap Highlights: Reported positive data from the randomized, controlled Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line colorectal cancer (CRC) patients demonstrating significantly higher overall response rate (ORR) and longer progression-free survival (PFS) across DKK1-high and VEGF-naïve subgroupsHosted virtual key opinion leader (KOL) event featuring Zev A. Wainberg, MD, to further discuss the
U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction REHOVOT, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today the appointment of Shai Lankry as its Chief Financial Officer. "We are pleased to welcome Shai on board. His extensive experience in the U.S. and European biotech and pharma marke
Live finance-specific insights
CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (NASDAQ:LPTX), a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash, today reported financial results for the third quarter of 2025 and a corporate update. As announced earlier today, the Company has changed its name to "Cypherpunk Technologies Inc." from "Leap Therapeutics, Inc." to reflect the strategic focus on acquiring the digital asset, ZEC, participating in the development of Zcash, and the values of privacy and liberty. The Company will begin trading on the Nasdaq Capital Market under the
Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Leap to continue supporting development of sirexatamab in DKK1-high CRC patients CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced final results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and ch
CAMBRIDGE, Mass., Oct. 6, 2025 /PRNewswire/ -- Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced $58,888,888 in cash commitments for a private investment in public equity ("PIPE") offering led by Winklevoss Capital to initiate a digital asset treasury strategy. Leap has entered into a securities purchase agreement for the purchase and sale of (i) 95,849,353 shares of common stock (the "Purchased Shares") or pre-funded warrants in lieu thereof (the "Purchased Pre-Funded Warrants") and (ii) warrants to purchase an additional 71,887,008 shares of common stock at an exercise price of $0.5335 per share (the "P
CAMBRIDGE, Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025. Leap Highlights: Board of Directors initiated process of exploring strategic alternatives to maximize shareholder valueStrategic restructuring to prioritize corporate development resulting in a further 75% reduction in workforceReported updated data from the randomized, controlled Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line colorectal cancer (CRC)"This past quarter, we undertook a strategic
Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024. Leap Highlights: Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) in second-line patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) confirming:Statistically significant 32% higher overall response rate (ORR), 3.5 month longer progression-free survival (P
Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prior anti-VEGF therapy Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe study (NCT05480306), a Phase 2, open-label, g
35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 levels highly correlated with clinical activity in CRC population ORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populations Preparations will begin for a registrational Phase 3 study in second-line CRC patients DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations, but not the signal necessary to advance into Phase 3 Leap to host a conference call to present clinical data today, January 28, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., Jan.
CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024. Leap Highlights: Completed enrollment in the expanded randomized controlled Part B of the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-DKK1 monoclonal antibody, in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC); data expected in mid-2025Patient follow-up continuing in the randomized controlled Part C of the Phase 2 DisTinGuish study evaluating DKN-01 in
CAMBRIDGE, Mass., Aug. 12, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024. Leap Highlights: Overall response rate (ORR) increases to 33% across all evaluable patients and 38% across evaluable patients with left-sided CRC in updated data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC)Expanded the randomized controlled Part B of the DeFianCe study to 180 patients; enrollment expected to be comple
CAMBRIDGE, Mass., May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024. Leap Highlights: Completed $40 million private placement financing with participation from Gilead Sciences, Inc., a life sciences-focused investor, Samsara BioCapital, 683 Capital Partners, LP, Laurion Capital Management, and Rock Springs CapitalPresented clinical data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal ca
This live feed shows all institutional transactions in real time.
SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
Live Leadership Updates
Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cypherpunk Technologies Inc. announces acquisition of 203,775.27 ZEC. CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today announced it will change its name to Cypherpunk Technologies Inc., and unveiled a digital asset treasury strategy to accumulate Zcash's native coin, ZEC. Cypherpunk has to date used $50 million of proceeds from the previously announced private placement to purchase 203,775.27 ZEC at an average purchase price of $245.37 per ZEC. In addition, the company also plans to change its ticker symbol to (NASDAQ:CYPH) as part of t
CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug development and clinical trials for a wide range of cancers. "We are honored to welcome Dr. Schilsky, who brings a wealth of experience and deep knowledge to bolster Leap's drug development strategy," said Christopher Mirabelli, PhD, Chairman of Leap Therapeutics' Board. "He is a